Trial Profile
Hungarian Multicenter Non-Interventional Study of Continued Avastin (Bevacizumab) Plus Chemotherapy Until First Progression Following Induction Treatment With Chemotherapy Doublet Plus Avastin in First Line Treatment of Patients With Metastatic Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AVACONT
- Sponsors Roche
- 27 Mar 2018 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.